Table 1.

Clinical data of patients with WG

pat	Age	Sex	Duration of disease (months)	Disease activity	i.s. treatment	Antibiotic treatment
1	45	m	2	active	Pr.	CT
2	52	f	69	active	–	–
3	34	m	100	active	Cy.	CT
4	54	m	20	active	Cy.	MC
5	71	f	118	active	Cy.	–
6	51	m	87	active	–	CT
7	53	f	n.p.	active	–	–
8	56	m	250	active	–	CT, MP
9	31	f	106	quiescent	–	CT
10	59	f	27	quiescent	–	–
11	57	m	4	quiescent	–	–
12	25	f	16	quiescent	Aza	CT
13	63	m	149	quiescent	–	–
14	54	m	130	quiescent	–	CT
15	28	f	95	quiescent	–	–
16	78	m	118	quiescent	–	–
17	64	f	54	quiescent	–	–
18	69	m	72	quiescent	Cy., Pr.	CT
19	67	m	55	quiescent	–	–
20	68	f	119	quiescent	–	–
21	69	m	229	quiescent	–	MP
22	86	m	178	quiescent	–	–
23	67	f	286	quiescent	–	CT
24	86	f	107	quiescent	–	–
25	65	m	48	quiescent	–	–
26	45	m	154	quiescent	Pr.	CT
27	78	m	120	quiescent	–	CT
28	72	f	181	quiescent	–	CT
29	27	f	114	quiescent	Pr.	–
30	81	f	20	quiescent	Aza.	–
31	27	f	18	quiescent	Aza.	CT
32	68	m	36	quiescent	–	–
33	47	f	121	quiescent	–	–
34	64	f	156	quiescent	–	–
35	75	m	38	quiescent	–	–
36	56	f	160	quiescent	–	–
37	28	f	29	quiescent	–	–
38	20	m	118	quiescent	–	–

Abbreviations: pat; patient, Aza: azathioprine; CT: cotrimoxazole; Cy: cyclophosphamide; MC: minocyclin; MP: mupirocin; i.s. immunosuppressive; n.p. new patient. The dosage of treatment is described in the Methods section.